MP12-04 PATIENT-CENTERED FACTORS ASSOCIATED WITH QUALITY OF LIFE AMONG BLADDER CANCER SURVIVORS

Abstract

You have accessJournal of UrologyGeneral & Epidemiological Trends & Socioeconomics: Practice Patterns, Quality of Life and Shared Decision Making II (MP12)1 Apr 2020MP12-04 PATIENT-CENTERED FACTORS ASSOCIATED WITH QUALITY OF LIFE AMONG BLADDER CANCER SURVIVORS Kathryn Gessner*, Sean McCabe, Judy Hamad, Amy Guo, Allison Deal, John Gore, and Angela Smith Kathryn Gessner*Kathryn Gessner* More articles by this author , Sean McCabeSean McCabe More articles by this author , Judy HamadJudy Hamad More articles by this author , Amy GuoAmy Guo More articles by this author , Allison DealAllison Deal More articles by this author , John GoreJohn Gore More articles by this author , and Angela SmithAngela Smith More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000832.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Bladder cancer requires treatment and surveillance which varies in intensity by disease stage and may be experienced differently based on age and gender. Our objective was to identify patient-centered factors associated with generic and bladder cancer-specific quality of life (QOL) among a large cohort of bladder cancer survivors. METHODS: We performed a cross-sectional survey of bladder cancer patients using the Bladder Cancer Advocacy Network Patient Survey Network and Inspire platforms to determine generic and bladder cancer-specific QOL using the EORTC QLQ-C30 and Bladder Cancer Index. Patients were also queried regarding demographic, socioeconomic and clinical characteristics. We present descriptive statistics and a multiple linear regression model controlling for age, race, gender, stage, comorbidity and time since diagnosis to identify factors independently associated with QOL domain score. RESULTS: 972 respondents self-identified as patients with bladder cancer. Among respondents, 41% were female and 97% were white. The mean age was 67.6 years (range 29 to 93 years). Patients identified as having non-muscle-invasive bladder cancer (n=578 [63%]), muscle-invasive bladder cancer (n=270 [30%]), and metastatic bladder cancer (n=63 [7%]). On multivariable analysis, female gender was significantly associated with worse generic QOL (p<0.001), bowel function (p=0.001), and sexual function (p=0.02). Higher stage was likewise associated with worse generic, urinary, sexual, and bowel QOL (p<0.01) while older age was associated with better generic QOL (p<0.01) and urinary function (p<0.01) but not sexual or bowel function. CONCLUSIONS: Higher stage, female gender and younger age appears to negatively impact generic and bladder cancer-specific QOL among bladder cancer survivors. Differential impact of specific patient-centered factors on specific QOL domains may be important for the development of tailored interventions to improve QOL for all bladder cancer patients. Source of Funding: BCAN Patient Survey Network Award Sponsored by Ferring Pharmaceuticals © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e145-e145 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kathryn Gessner* More articles by this author Sean McCabe More articles by this author Judy Hamad More articles by this author Amy Guo More articles by this author Allison Deal More articles by this author John Gore More articles by this author Angela Smith More articles by this author Expand All Advertisement PDF downloadLoading ...